KEGG   DRUG: Casimersen
Entry
D11988                      Drug                                   
Name
Casimersen (USAN/INN);
Amondys 45 (TN)
Product
AMONDYS 45 (Sarepta Therapeutics)
Formula
C268H424N124O95P22
Exact mass
7580.6386
Mol weight
7584.4307
Remark
ATC code: M09AX13
Product: D11988<US>
Efficacy
Translation inhibitor
  Disease
Duchenne muscular dystrophy (DMD variant amenable to exon 45 skipping) [DS:H01963]
  Type
Antisense oligonucleotide
Comment
Treatment of Duchenne muscular dystrophy
Target
DMD* [HSA_VAR:1756v1] [HSA:1756] [KO:K10366] (pre-mRNA exon45)
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 M MUSCULO-SKELETAL SYSTEM
  M09 OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM
   M09A OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM
    M09AX Other drugs for disorders of the musculo-skeletal system
     M09AX13 Casimersen
      D11988  Casimersen (USAN/INN) <US>
USP drug classification [BR:br08302]
 Genetic, Enzyme, or Protein Disorder: Replacement, Modifiers, Treatment
  Casimersen
   D11988  Casimersen (USAN/INN)
Target-based classification of drugs [BR:br08310]
 Not elsewhere classified
  Cellular process
   Cytoskeleton
    DMD* [HSA_VAR:1756v1]
     D11988  Casimersen (USAN/INN) <US>
New drug approvals in the USA [br08319.html]
 New molecular entities and new therapeutic biological products
  D11988
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D11988
Pharmacogenomic biomarkers [br08341.html]
 Germline mutations in genetic disorder treatments
  D11988
Other DBs
CAS: 1422958-19-7
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system